Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Japan Helps Bayer’s Eylea Sales To Sparkle

Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.

Cancer Sales & Earnings Ophthalmic

After Another Covid Vaccine Delay, Novavax’s Opportunity Is Shrinking

Novavax’s timelines are slipping once again, giving frontrunners Pfizer and Moderna the chance to consolidate their dominance in the market.

Commercial Companies Coronavirus COVID-19

Companies

Set Alert for Companies

Latest From Companies

Curis And Autolus Rise On EHA Abstract Data

Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.

Commercial Companies

Leyden Labs Targets Viral Families To Head Off Next Pandemic

Emerging Company Profile: While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.

StartUps and SMEs Clinical Trials

Genfit’s Post-NASH Plans Center On ACLF, Cholestatic Liver Disease

After last year’s Phase III failure in NASH, Genfit sees big opportunity in acute on chronic liver failure (ACLF), potentially with antiviral NTX. Its ongoing Phase III program in PBC as also is a potential revenue-driver.

Business Strategies Companies

AstraZeneca Sees Off Shareholder Revolt Over CEO’s Potential $25m Pay

A few years ago Pascal Soriot claimed to be the sector’s worst paid CEO, but share price-linked bonuses have bumped up his remuneration, and shareholders have now approved a new plan.

Companies Commercial

Quick Listen: The Story Behind The Pharmaprojects’ Pharma R&D Annual Review 2021

In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.

Research & Development Companies

As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations

Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.

Companies Commercial
See All

Deals

Set Alert for Deals

Latest From Deals

Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids

Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.

Gene Therapy Deals

Eli Lilly To Explore MiNA's Small Activating RNA Technology

Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.

Deals Financing

As Lilly Seals Licensing Deals For Olumiant, What Next For Challenger Natco?

Lilly signs licensing pacts with Cipla, Sun and Lupin for baricitinib in COVID-19, with possibly more in store. But will challenger Natco, which has apparently already rolled out its cut-price version of the JAK inhibitor, change tack amid the Indian government's mixed position on compulsory licensing issues in an ongoing court case?

India Intellectual Property

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Deals Business Strategies

Abingworth Offers Home For Big Pharma Pipeline Projects

The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.

Financing Clinical Trials

Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.

Deals Research and Development Strategies
See All

Strategy

Set Alert for Strategy

Latest From Strategy

More Competition Coming To Cushing's Market

Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space

Rare Diseases Strategy

Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo

Libtayo is the first immunotherapy to demonstrate an improvement in OS, PFS and ORR in advanced cervical cancer and approval in this indication could kickstart its lackluster sales to date.

ImmunoOncology Clinical Trials

Galapagos Puts Faith In Refocused Pipeline To Regain Investor Confidence

The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."

Leadership Strategy

Chiesi Keen To Nurture Disruptive Innovation

Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.

Leadership Strategy

Amryt Predicts $1bn Revenues After Chiasma Acquisition

The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.

M & A Rare Diseases

Will Beovu Be A Slow-Burning Blockbuster?

Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.

Ophthalmic Clinical Trials
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Pressure Mounts On EU To Follow US In Backing COVID-19 Vaccine IP Waiver

The pharmaceutical industry in Europe has attacked the US decision to come out in support of a relaxation of IP rights that is designed to boost global production of COVID-19 vaccines. But the move by the Biden administration could well cause other countries to rethink their opposition to the move.

Coronavirus COVID-19 Intellectual Property

Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Immune Disorders Launches

Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap

Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.

Commercial Companies
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

A Dramatically Changing Landscape In Acute Myeloid Leukemia

Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.

Market Intelligence Cancer

The 2021 Worldwide Pharma And Biotech R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.

Companies Market Intelligence

With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?

Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.

Market Intelligence Cancer
See All
UsernamePublicRestriction

Register